Evaluating the Relationship Between Hypertriglyceridemia and Cardiovascular Risk

1
Evaluating the Relationship Between
Hypertriglyceridemia and Cardiovascular Risk
2
Case Study 45-year-old Man
3
Case Study 45-year-old Man (cont)
4
Medications and Lab Results
5
Primary Causes of Hypertriglyceridemia
6
Secondary Causes of Hypertriglyceridemia
7
Triglyceride Level Is a Significant CVD Risk
Factor Recent Meta-Analysis of 29 Studies
8
ATP III Treatment Recommendations for Elevated TGs
9
The Chemical Differences Between EPA and DHA
10
Select Omega-3 Outcomes Studies
11
Icosapent Ethyl (Pure EPA) Median
Placebo-Adjusted Change From Baseline for
Efficacy End Points
12
(No Transcript)
13
(No Transcript)
14
(No Transcript)
15
ANCHOR Icosapent Ethyl Change in Lipid End Points
16
Reduction of Cardiovascular Events With EPA
Intervention Trial
17
Primum Non Nocere
18
Abbreviations
19
Abbreviations (cont)
20
Abbreviations (cont)
21
References
22
References (cont)
23
References (cont)
24
References (cont)